Prot #COMB157BUS25T//NU 10H06: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Project: Research project

Project Details

StatusActive
Effective start/end date4/21/1112/31/22

Funding

  • Novartis Pharmaceuticals Corporation (Prot #COMB157BUS25T//NU 10H06)